Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 2 years
- Director since
- 2024
2 years of board service in total across 1 board, counting each seat separately. Longest: Mineralys Therapeutics Inc., 2 years.
Mineralys Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 19, 2026 | Mineralys Therapeutics Inc. | Grant or award | +6,200 | — | — |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Option exercise | +2,742 | $10.20 | $27,968 |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Option exercise | +10,000 | $12.69 | $126,900 |
| Nov 13, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −12,742 | $46.50 | $592,503 |
| Nov 12, 2025 | Mineralys Therapeutics Inc. | Option exercise | +6,933 | $10.20 | $70,717 |
| Nov 12, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −5,000 | $46.50 | $232,500 |
| Nov 12, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −1,933 | $47.28 | $91,392 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Option exercise | +15,000 | $10.20 | $153,000 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −10,000 | $42.43 | $424,300 |
| Nov 11, 2025 | Mineralys Therapeutics Inc. | Open-market sale | −5,000 | $47.08 | $235,400 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.